Prostaglandin synthesis inhibitors in menorrhagia, intrauterine contraceptive device-induced side effects and endometriosis.
Primary menorrhagia, IUD side effects and endometriotic symptoms may be a result of excessive PG release in the reproductive organs. These conditions and symptoms can be prevented or markedly alleviated by a PG synthesis inhibitor, such as tolfenamic acid. This treatment, which is used only intermittently, has been well tolerated with no serious side effects.
Ylikorkala
O
O
Department of Obstetrics and Gynaecology, University of Helsinki, Finland.
D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004715:Endometriosis / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007434:Intrauterine Devices / Q000009:adverse effects; D008595:Menorrhagia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D011448:Prostaglandin Antagonists; D011453:Prostaglandins / Q000502:physiology; D012107:Research Design; D062367:ortho-Aminobenzoates / Q000627:therapeutic use*
D016861:Cyclooxygenase Inhibitors; D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D062367:ortho-Aminobenzoates; C009500:tolfenamic acid